{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T21:02:07Z","timestamp":1795035727288,"version":"4.10.2"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T00:00:00Z","timestamp":1591056000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T00:00:00Z","timestamp":1591056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"'Conseil r\u00e9gional du Nord-Pas-de-Calais'"},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Association Cassandra contre la leuc\u00e9mie"},{"name":"Soci\u00e9t\u00e9 Fran\u00e7aise de lutte contre les cancers et les leuc\u00e9mies de l'enfant et de l'adolescent","id":[{"id":"https:\/\/ror.org\/04m40v102","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Association l'\u00e9toile de Martin"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Fluids Barriers CNS"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pediatric diffuse intrinsic pontine glioma (DIPG) represents one of the most devastating and lethal brain tumors in children with a median survival of 12\u00a0months. The high mortality rate can be explained by the ineligibility of patients to surgical resection due to the diffuse growth pattern and midline localization of the tumor. While the therapeutic strategies are unfortunately palliative, the blood\u2013brain barrier (BBB) is suspected to be responsible for the treatment inefficiency. Located at the brain capillary endothelial cells (ECs), the BBB has specific properties to tightly control and restrict the access of molecules to the brain parenchyma including chemotherapeutic compounds. However, these BBB specific properties can be modified in a pathological environment, thus modulating brain exposure to therapeutic drugs. Hence, this study aimed at developing a syngeneic human blood\u2013brain tumor barrier model to understand how the presence of DIPG impacts the structure and function of\u00a0brain capillary ECs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A human syngeneic in vitro BBB model consisting of a triple culture of human (ECs) (differentiated from CD34\n                      <jats:sup>+<\/jats:sup>\n                      -stem cells), pericytes and astrocytes was developed. Once validated in terms of BBB phenotype, this model was adapted to develop a blood\u2013brain tumor barrier (BBTB) model specific to pediatric DIPG by replacing the astrocytes by DIPG-007, -013 and -014 cells. The physical and metabolic properties of the BBTB ECs were analyzed and compared to the BBB ECs. The permeability of both models to chemotherapeutic compounds was evaluated.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In line with clinical observation, the integrity of the BBTB ECs remained intact until 7\u00a0days of incubation. Both transcriptional expression and activity of efflux transporters were not strongly modified by the presence of DIPG. The permeability of ECs to the chemotherapeutic drugs temozolomide and panobinostat was not affected by the DIPG environment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This original human BBTB model allows a better understanding of the influence of DIPG on the BBTB ECs phenotype. Our data reveal that the chemoresistance described for DIPG does not come from the development of a \u201csuper BBB\u201d. These results, validated by the absence of modification of drug transport through the BBTB ECs, point out the importance of understanding the implication of the different protagonists in the pathology to have a chance to significantly improve treatment efficiency.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12987-020-00198-0","type":"journal-article","created":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T08:04:34Z","timestamp":1591085074000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["Development of a human in vitro blood\u2013brain tumor barrier model of diffuse intrinsic pontine glioma to better understand the chemoresistance"],"prefix":"10.1186","volume":"17","author":[{"given":"Cl\u00e9mence","family":"Deligne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Hachani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Duban-Deweer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Meignan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Leblond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel M.","family":"Carcaboso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuteru","family":"Sano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumitaka","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Gosselet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Pierre","family":"Dehouck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Mysiorek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,2]]},"reference":[{"key":"198_CR1","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1177\/0883073815601495","volume":"31","author":"T Hennika","year":"2016","unstructured":"Hennika T, Becher OJ. Diffuse intrinsic pontine glioma: time for cautious optimism. J Child Neurol. 2016;31:1377\u201385.","journal-title":"J Child Neurol"},{"key":"198_CR2","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","volume":"131","author":"DN Louis","year":"2016","unstructured":"Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131:803\u201320.","journal-title":"Acta Neuropathol"},{"key":"198_CR3","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.critrevonc.2017.10.013","volume":"120","author":"HS Gwak","year":"2017","unstructured":"Gwak HS, Park HJ. Developing chemotherapy for diffuse pontine intrinsic gliomas (DIPG). Crit Rev Oncol Hematol. 2017;120:111\u20139.","journal-title":"Crit Rev Oncol Hematol"},{"key":"198_CR4","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s11060-019-03287-9","volume":"145","author":"FE El-Khouly","year":"2019","unstructured":"El-Khouly FE, Veldhuijzen van Zanten SEM, Santa-Maria Lopez V, Hendrikse NH, Kaspers GJL, Loizos G, et al. Diagnostics and treatment of diffuse intrinsic pontine glioma: where do we stand? J Neurooncol. 2019;145:177\u201384.","journal-title":"J Neurooncol"},{"key":"198_CR5","first-page":"153","volume":"19","author":"C Jones","year":"2017","unstructured":"Jones C, Karajannis MA, Jones DTW, Kieran MW, Monje M, Baker SJ, et al. Pediatric high-grade glioma: biologically and clinically in need of new thinking. Neuro Oncol. 2017;19:153\u201361.","journal-title":"Neuro Oncol."},{"key":"198_CR6","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1200\/JCO.2009.26.7252","volume":"28","author":"BS Paugh","year":"2010","unstructured":"Paugh BS, Qu C, Jones C, Liu Z, Adamowicz-Brice M, Zhang J, et al. Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J Clin Oncol. 2010;28:3061.","journal-title":"J Clin Oncol"},{"key":"198_CR7","doi-asserted-by":"publisher","first-page":"172","DOI":"10.3389\/fonc.2015.00172","volume":"5","author":"KL Misuraca","year":"2015","unstructured":"Misuraca KL, Cordero FJ, Becher OJ. Pre-clinical models of diffuse intrinsic pontine glioma. Front Oncol. 2015;5:172.","journal-title":"Front Oncol"},{"issue":"8","key":"198_CR8","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.3390\/ijms17081309","volume":"17","author":"A Drolez","year":"2016","unstructured":"Drolez A, Vandenhaute E, Delannoy CP, Dewald JH, Gosselet F, Cecchelli R, et al. ST6GALNAC5 expression decreases the interactions between breast cancer cells and the human blood\u2013brain barrier. Int J Mol Sci. 2016;17(8):1309.","journal-title":"Int J Mol Sci"},{"key":"198_CR9","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1124\/dmd.108.024745","volume":"37","author":"S Syv\u00e4nen","year":"2009","unstructured":"Syv\u00e4nen S, Lindhe \u00d6, Palner M, Kornum BR, Rahman O, L\u00e5ngstr\u00f6m B, et al. Species differences in blood\u2013brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport. Drug Metab Dispos. 2009;37:635\u201343.","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"198_CR10","doi-asserted-by":"publisher","first-page":"e61512","DOI":"10.1371\/journal.pone.0061512","volume":"8","author":"SJE Veringa","year":"2013","unstructured":"Veringa SJE, Biesmans D, van Vuurden DG, Jansen MH, Wedekind LE, Horsman I, et al. In vitro drug response and efflux transporters associated with drug resistance in pediatric high grade glioma and diffuse intrinsic pontine glioma. PLoS ONE. 2013;8(4):e61512.","journal-title":"PLoS ONE"},{"key":"198_CR11","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrn1824","volume":"7","author":"NJ Abbott","year":"2006","unstructured":"Abbott NJ, R\u00f6nnb\u00e4ck L, Hansson E. Astrocyte-endothelial interactions at the blood\u2013brain barrier. Nat Rev Neurosci. 2006;7:41.","journal-title":"Nat Rev Neurosci"},{"issue":"3","key":"198_CR12","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s10545-013-9608-0","volume":"36","author":"NJ Abbott","year":"2013","unstructured":"Abbott NJ. Blood\u2013brain barrier structure and function and the challenges for CNS drug delivery. J Inherit Metab Dis. 2013;36(3):437\u201349.","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"198_CR13","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1152\/physrev.00050.2017","volume":"99","author":"MD Sweeney","year":"2019","unstructured":"Sweeney MD, Zhao Z, Montagne A, Nelson AR, Zlokovic BV. Blood\u2013brain barrier: from physiology to disease and back. Physiol Rev. 2019;99(1):21\u201378.","journal-title":"Physiol Rev"},{"issue":"6","key":"198_CR14","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/nn.4288","volume":"19","author":"MD Sweeney","year":"2016","unstructured":"Sweeney MD, Ayyadurai S, Zlokovic BV. Pericytes of the neurovascular unit: key functions and signaling pathways. Nat Neurosci. 2016;19(6):771\u201383.","journal-title":"Nat Neurosci"},{"key":"198_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pneurobio.2014.11.003","volume":"125","author":"AM Hopkins","year":"2015","unstructured":"Hopkins AM, DeSimone E, Chwalek K, Kaplan DL. 3D in vitro modeling of the central nervous system. Prog Neurobiol. 2015;125:1\u201325.","journal-title":"Prog Neurobiol"},{"issue":"1","key":"198_CR16","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3390\/pharmaceutics12010020","volume":"12","author":"D Gomez-Zepeda","year":"2020","unstructured":"Gomez-Zepeda D, Taghi M, Scherrmann JM, Decleves X, Menet MC. ABC transporters at the blood\u2013brain interfaces, their study models, and drug delivery implications in gliomas. Pharmaceutics. 2020;12(1):20.","journal-title":"Pharmaceutics."},{"issue":"5","key":"198_CR17","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3390\/pharmaceutics11050245","volume":"11","author":"A Parodi","year":"2019","unstructured":"Parodi A, Rudzi\u0144ska M, Deviatkin AA, Soond SM, Baldin AV, Zamyatnin AA. Established and emerging strategies for drug delivery across the blood\u2013brain barrier in brain cancer. Pharmaceutics. 2019;11(5):245.","journal-title":"Pharmaceutics."},{"key":"198_CR18","doi-asserted-by":"publisher","unstructured":"Saunders NR, Habgood MD, M\u00f8llg\u00e5rd K, Dziegielewska KM. The biological significance of brain barrier mechanisms: help or hindrance in drug delivery to the central nervous system? F1000Res. 2016. https:\/\/doi.org\/10.12688\/f1000research.7378.1.","DOI":"10.12688\/f1000research.7378.1"},{"issue":"3","key":"198_CR19","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.biochi.2007.10.007","volume":"90","author":"F Dutheil","year":"2008","unstructured":"Dutheil F, Beaune P, Loriot MA. Xenobiotic metabolizing enzymes in the central nervous system: contribution of cytochrome P450 enzymes in normal and pathological human brain. Biochimie. 2008;90(3):426\u201336.","journal-title":"Biochimie"},{"issue":"8","key":"198_CR20","doi-asserted-by":"publisher","first-page":"732","DOI":"10.2174\/138920011798357024","volume":"12","author":"X Decleves","year":"2011","unstructured":"Decleves X, Jacob A, Yousif S, Shawahna R, Potin S, Scherrmann J-M. Interplay of drug metabolizing CYP450 enzymes and ABC transporters in the blood\u2013brain barrier. Curr Drug Metab. 2011;12(8):732\u201341.","journal-title":"Curr Drug Metab"},{"key":"198_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drup.2015.02.002","volume":"19","author":"O Van Tellingen","year":"2015","unstructured":"Van Tellingen O, Yetkin-Arik B, De Gooijer MC, Wesseling P, Wurdinger T, De Vries HE. Overcoming the blood\u2013brain tumor barrier for effective glioblastoma treatment. Drug Resist Updates. 2015;19:1\u20132.","journal-title":"Drug Resist Updates"},{"issue":"3","key":"198_CR22","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3340\/jkns.2018.0008","volume":"61","author":"RK Mathew","year":"2018","unstructured":"Mathew RK, Rutka JT. Diffuse intrinsic pontine glioma: clinical features, molecular genetics, and novel targeted therapeutics. J Korean Neurosurg Soc. 2018;61(3):343.","journal-title":"J Korean Neurosurg Soc"},{"issue":"1","key":"198_CR23","doi-asserted-by":"publisher","first-page":"e16114","DOI":"10.1371\/journal.pone.0016114","volume":"6","author":"DC Pedroso","year":"2011","unstructured":"Pedroso DC, Tellechea A, Moura L, Fidalgo-Carvalho I, Duarte J, Carvalho E, et al. Improved survival, vascular differentiation and wound healing potential of stem cells co-cultured with endothelial cells. PLoS ONE. 2011;6(1):e16114.","journal-title":"PLoS ONE"},{"issue":"1","key":"198_CR24","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1002\/jcp.22337","volume":"226","author":"F Shimizu","year":"2011","unstructured":"Shimizu F, Sano Y, Abe MA, Maeda T, Ohtsuki S, Terasaki T, et al. Peripheral nerve pericytes modify the blood\u2013nerve barrier function and tight junctional molecules through the secretion of various soluble factors. J Cell Physiol. 2011;226(1):255\u201366.","journal-title":"J Cell Physiol"},{"issue":"6","key":"198_CR25","doi-asserted-by":"publisher","first-page":"e99733","DOI":"10.1371\/journal.pone.0099733","volume":"9","author":"R Cecchelli","year":"2014","unstructured":"Cecchelli R, Aday S, Sevin E, Almeida C, Culot M, Dehouck L, et al. A stable and reproducible human blood\u2013brain barrier model derived from hematopoietic stem cells. PLoS ONE. 2014;9(6):e99733.","journal-title":"PLoS ONE"},{"issue":"5","key":"198_CR26","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/ng.2925","volume":"46","author":"KR Taylor","year":"2014","unstructured":"Taylor KR, Mackay A, Truffaux N, Butterfield YS, Morozova O, Philippe C, et al. Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma. Nat Genet. 2014;46(5):457.","journal-title":"Nat Genet"},{"issue":"2","key":"198_CR27","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1002\/jcp.21508","volume":"217","author":"F Shimizu","year":"2008","unstructured":"Shimizu F, Sano Y, Maeda T, Abe MA, Nakayama H, Takahashi RI, et al. Peripheral nerve pericytes originating from the blood\u2013nerve barrier expresses tight junctional molecules and transporters as barrier-forming cells. J Cell Physiol. 2008;217(2):388\u201399.","journal-title":"J Cell Physiol"},{"key":"198_CR28","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3389\/fncel.2016.00020","volume":"10","author":"A Trost","year":"2016","unstructured":"Trost A, Lange S, Schroedl F, Bruckner D, Motloch KA, Bogner B, et al. Brain and retinal pericytes: origin, function and role. Front Cell Neurosci. 2016;10:20.","journal-title":"Front Cell Neurosci"},{"key":"198_CR29","doi-asserted-by":"publisher","first-page":"215135","DOI":"10.1155\/2015\/215135","volume":"2015","author":"D Rizzo","year":"2015","unstructured":"Rizzo D, Ruggiero A, Martini M, Rizzo V, Maurizi P, Riccardi R. Molecular biology in pediatric high-grade glioma: impact on prognosis and treatment. Biomed Res Int. 2015;2015:215135. https:\/\/doi.org\/10.1155\/2015\/215135.","journal-title":"Biomed Res Int."},{"issue":"3","key":"198_CR30","doi-asserted-by":"publisher","first-page":"e0151155","DOI":"10.1371\/journal.pone.0151155","volume":"11","author":"A Drolez","year":"2016","unstructured":"Drolez A, Vandenhaute E, Julien S, Gosselet F, Burchell J, Cecchelli R, et al. Selection of a relevant in vitro blood\u2013brain barrier model to investigate pro-metastatic features of human breast cancer cell lines. PLoS One. 2016;11(3):e0151155. https:\/\/doi.org\/10.1371\/journal.pone.0151155.","journal-title":"PLoS One."},{"issue":"8","key":"198_CR31","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1158\/0008-5472.CAN-16-2850","volume":"77","author":"S Kossatz","year":"2017","unstructured":"Kossatz S, Carney B, Schweitzer M, Carlucci G, Miloushev VZ, Maachani UB, et al. Biomarker-based PET imaging of diffuse intrinsic pontine glioma in mouse models. Cancer Res. 2017;77(8):2112\u201323.","journal-title":"Cancer Res"},{"issue":"3","key":"198_CR32","doi-asserted-by":"publisher","first-page":"e0118926","DOI":"10.1371\/journal.pone.0118926","volume":"10","author":"KG Halvorson","year":"2015","unstructured":"Halvorson KG, Barton KL, Schroeder K, Misuraca KL, Hoeman C, Chung A, et al. A high-throughput in Vitro drug screen in a genetically engineered mouse model of diffuse intrinsic pontine glioma identifies BMS-754807 as a promising therapeutic agent. PLoS One. 2015;10(3):e0118926. https:\/\/doi.org\/10.1371\/journal.pone.0118926.","journal-title":"PLoS One."},{"issue":"5","key":"198_CR33","doi-asserted-by":"publisher","first-page":"399","DOI":"10.3390\/pharmaceutics12050399","volume":"12","author":"C Chaves","year":"2020","unstructured":"Chaves C, Decl\u00e8ves X, Taghi M, Menet MC, Lacombe J, Varlet P, Olaciregui NG, Carcaboso AMCS. Characterization of the blood\u2013brain barrier integrity and the brain transport of SN-38 in an orthotopic xenograft rat model of diffuse intrinsic pontine glioma. Pharmaceutics. 2020;12(5):399.","journal-title":"Pharmaceutics."},{"key":"198_CR34","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3389\/fonc.2018.00239","volume":"8","author":"KE Warren","year":"2018","unstructured":"Warren KE. Beyond the blood: brain barrier: the importance of central nervous system (CNS) pharmacokinetics for the treatment of CNS tumors, including diffuse intrinsic pontine glioma. Front Oncol. 2018;8:239.","journal-title":"Front Oncol"},{"issue":"2","key":"198_CR35","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s11060-015-1969-9","volume":"126","author":"E Subashi","year":"2016","unstructured":"Subashi E, Cordero FJ, Halvorson KG, Qi Y, Nouls JC, Becher OJ, et al. Tumor location, but not H3.3K27M, significantly influences the blood\u2013brain-barrier permeability in a genetic mouse model of pediatric high-grade glioma. J Neurooncol. 2016;126(2):243\u201351.","journal-title":"J Neurooncol"},{"issue":"1","key":"198_CR36","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/pr.2013.194","volume":"75","author":"KM Schroeder","year":"2014","unstructured":"Schroeder KM, Hoeman CM, Becher OJ. Children are not just little adults: recent advances in understanding of diffuse intrinsic pontine glioma biology. Pediatr Res. 2014;75(1):205\u20139.","journal-title":"Pediatr Res"},{"issue":"1","key":"198_CR37","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","volume":"20","author":"CD Arvanitis","year":"2020","unstructured":"Arvanitis CD, Ferraro GB, Jain RK. The blood\u2013brain barrier and blood\u2013tumour barrier in brain tumours and metastases. Nat Rev Cancer. 2020;20(1):26\u201341. https:\/\/doi.org\/10.1038\/s41568-019-0205-x.","journal-title":"Nat Rev Cancer."},{"issue":"3","key":"198_CR38","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1023\/A:1022592913323","volume":"61","author":"M Patel","year":"2003","unstructured":"Patel M, McCully C, Godwin K, Balis FM. Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates. J Neurooncol. 2003;61(3):203\u20137.","journal-title":"J Neurooncol"},{"issue":"7","key":"198_CR39","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1097\/CAD.0000000000000238","volume":"26","author":"U Linz","year":"2015","unstructured":"Linz U, Hupert M, Santiago-Sch\u00fcbel B, Wien S, Stab J, Wagner S. Transport of treosulfan and temozolomide across an in vitro blood\u2013brain barrier model. Anticancer Drugs. 2015;26(7):728\u201336.","journal-title":"Anticancer Drugs"},{"issue":"3","key":"198_CR40","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s00018-013-1397-y","volume":"71","author":"C Riganti","year":"2014","unstructured":"Riganti C, Salaroglio IC, Pinz\u00f2n-Daza ML, Caldera V, Campia I, Kopecka J, et al. Temozolomide down-regulates P-glycoprotein in human blood\u2013brain barrier cells by disrupting Wnt3 signaling. Cell Mol Life Sci. 2014;71(3):499\u2013516.","journal-title":"Cell Mol Life Sci"},{"key":"198_CR41","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/nm.3855","volume":"21","author":"CS Grasso","year":"2015","unstructured":"Grasso CS, Tang Y, Truffaux N, Berlow NE, Liu L, Debily MA, et al. Functionally defined therapeutic targets in diffuse intrinsic pontine glioma. Nat Med. 2015;21:555.","journal-title":"Nat Med"},{"issue":"1","key":"198_CR42","doi-asserted-by":"publisher","first-page":"e0169485","DOI":"10.1371\/journal.pone.0169485","volume":"12","author":"T Hennika","year":"2017","unstructured":"Hennika T, Hu G, Olaciregui NG, Barton KL, Ehteda A, Chitranjan A, et al. Pre-clinical study of panobinostat in xenograft and genetically engineered murine diffuse intrinsic pontine glioma models. PLoS One. 2017;12(1):e0169485. https:\/\/doi.org\/10.1371\/journal.pone.0169485.","journal-title":"PLoS One."},{"key":"198_CR43","doi-asserted-by":"crossref","unstructured":"Louis Rodgers, Cynthia Lester McCully, Cody Peer, Rafael Cruz A, Figg W. Plasma and cerebrospinal fluid (CSF) pharmacokinetics of panobinostat following oral administration to non-human primates. In: Neuro-Oncology. 2016.","DOI":"10.1093\/neuonc\/now073.33"},{"key":"198_CR44","doi-asserted-by":"crossref","unstructured":"Rasmussen TA, Tolstrup M, M\u00f8ller HJ, Brinkmann CR, Olesen R, Erikstrup C, et al. Activation of latent human immunodeficiency virus by the histone deacetylase inhibitor panobinostat: a pilot study to assess effects on the central nervous system. In: Open Forum Infect Dis. 2015.","DOI":"10.1093\/ofid\/ofv037"},{"key":"198_CR45","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1016\/j.drudis.2016.06.004","volume":"21","author":"C Ghosh","year":"2016","unstructured":"Ghosh C, Hossain M, Solanki J, Dadas A, Marchi N, Janigro D. Pathophysiological implications of neurovascular P450 in brain disorders. Drug Discov Today. 2016;21:1609\u201319.","journal-title":"Drug Discov Today"},{"key":"198_CR46","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s40262-017-0565-x","volume":"57","author":"M Van Veggel","year":"2018","unstructured":"Van Veggel M, Westerman E, Hamberg P. Clinical pharmacokinetics and pharmacodynamics of panobinostat. Clin Pharmacokinet. 2018;57:21\u20139.","journal-title":"Clin Pharmacokinet"}],"container-title":["Fluids and Barriers of the CNS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12987-020-00198-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12987-020-00198-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12987-020-00198-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T22:23:42Z","timestamp":1666736622000},"score":1,"resource":{"primary":{"URL":"https:\/\/fluidsbarrierscns.biomedcentral.com\/articles\/10.1186\/s12987-020-00198-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,2]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["198"],"URL":"https:\/\/doi.org\/10.1186\/s12987-020-00198-0","relation":{},"ISSN":["2045-8118"],"issn-type":[{"value":"2045-8118","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,2]]},"assertion":[{"value":"21 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Human pericytes are from the cell line named HBPCT and were provided by Professor Takashi Kanda\u2019s group from Yamagushi University (Japan). The study protocol was approved by local ethic committee and conducted in accordance with the declaration of Helsinki, as amended in Somerset West in 1996 [\n                      \n                      ].The collection and use of CD34<sup>+<\/sup> -stem cells derived from cord blood has been approved since 2011 by the French ministry (CODECOH 2011-1321). These cells were harvested thanks to an agreement established between the hospital of B\u00e9thune and University of Artois. Informed consents were obtained from the families before starting the study.Patient-derived cells were obtained under an Institutional Review Board-approved protocol and with written informed consent (M-1608-C) at Hospital Sant Joan de Deu Barcelona, Spain.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"37"}}